Fluphenazine Decanoate

CHEMBL1200854 Phase 4 已批准 Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

591.8 g/mol

LogP

9.0

Phase

4

This long-acting injectable ester of fluphenazine is slowly released from the injection site over two to four weeks, providing sustained antipsychotic coverage. It is particularly useful for patients with schizophrenia who have difficulty adhering to daily oral medication.

分子量

591.8000 g/mol

LogP

9.00

TPSA

61.30 Å²

Lipinski 五规则

不符合

治疗领域

Schizophrenia Psoriasis

作用机制

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

机制

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

二维结构

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1

InChI

InChI=1S/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3

Molecular Formula

C32H44F3N3O2S

HBD / HBA

- / 9

可旋转键数

16

重原子数

41

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

This long-acting injectable ester of fluphenazine is slowly released from the injection site over two to four weeks, providing sustained antipsychotic coverage. It is particularly useful for patients with schizophrenia who have difficulty adhering to daily oral medication.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Fluphenazine Decanoate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200854. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3388. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

正在寻找患者友好型信息？

Fluphenazine Decanoate 在 PillFYI 上

结构

快速数据

分子式: C32H44F3N3O2S

外部链接

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.